1) To investigate the VDR levels in different MS associated T cell subsets2) to compare the VDR levels in the different T cell subsets between MS patients and age and gender matched healthy volunteers
ID
Source
Brief title
Condition
- Autoimmune disorders
- Central nervous system infections and inflammations
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The VDR expression levels will be determined both on the protein and mRNA
level. VDR protein and mRNA levels will be measured in different MS-associated
T cell subsets.
Secondary outcome
Next, VDR expression levels will be compared between RRMS patients and healthy
volunteers.
Background summary
Auto-immune diseases, like multiple sclerosis (MS) are less frequent around the
equator, where there is an equal amount of ultra violet B (UVB) radiation all
year. Also, an association between the vitamin D status and MS is found.
UVB-radiation is important for the vitamin D status and vitamin D influences
immune regulation. The idea is that at higher latitudes (away from the equator)
the vitamin D status is inadequate and that this influences immune regulation
and makes healthy individuals more prone to develop MS. Vitamin D exerts its
function via the vitamin D receptor (VDR). We hypothesize that a lower VDR
expression can contribute to an increased susceptibility to develop MS.
Therefore RRMS patients may have lower VDR levels in the different T cell
subsets as compared to healthy volunteers.
Study objective
1) To investigate the VDR levels in different MS associated T cell subsets
2) to compare the VDR levels in the different T cell subsets between MS
patients and age and gender matched healthy volunteers
Study design
cross sectional study
Study burden and risks
The only intervention that patients have to endure is a venepunction. The most
important risk of this is the development of a haematoma or a temporary
vasovagal reaction. To decrease these risks, the venepuncture will be performed
by a trained physician
PO Box 616
6200 MD Maastricht
Nederland
PO Box 616
6200 MD Maastricht
Nederland
Listed location countries
Age
Inclusion criteria
Relapsing-remitting MS patients
between 20-40 years
female
use of exclusively interferon beta (> 2 months)
Exclusion criteria
use of immune modulatory drugs other then interferon beta
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL28058.096.09 |